Vapotherm, Inc. (VAPO) News
Filter VAPO News Items
VAPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VAPO News Highlights
- VAPO's 30 day story count now stands at 2.
- Over the past 14 days, the trend for VAPO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VAPO News From Around the Web
Below are the latest news stories about Vapotherm Inc that investors may wish to consider to help them evaluate VAPO as an investment opportunity.
Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsEXETER, N.H., February 24, 2022--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders today announced fourth quarter and fiscal year 2021 financial results. |
Vapotherm to Report Fourth Quarter and Full Year 2021 Financial ResultsEXETER, N.H., February 10, 2022--Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders, today announced that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Vapotherm’s management team |
Vapotherm Stock: Speculative, but High-Upside IndustryI am neutral on Vapotherm (VAPO) as it operates in a high-upside, innovative industry and enjoys the support of Wall Street analysts with an average price target that implies massive upside over the next year. However, the company is very speculative as it is far from profitable and is currently facing declining revenue. Vapotherm develops medical technology products, specifically respiratory devices for treating breathing disorders. The company is focused on the commercialization of proprietary high velocity therapy products and currently offers flow systems, such as Precision Flow Classic, Precision Flow Heliox, and Precision Flow Plus. |
Is Vapotherm (NYSE:VAPO) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |
BTIG Thinks Vapotherm’s Stock is Going to RecoverBTIG analyst Marie Thibault reiterated a Buy rating on Vapotherm (VAPO – Research Report) today and set a price target of $45.00. The company's shares closed last Tuesday at $19.49, close to its 52-week low of $16.64. According to TipRanks.com, Thibault is a 5-star analyst with an average return of 29.4% and a 43.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vapotherm with a $41.00 average price target. |
Vapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue ResultsEXETER, N.H., January 12, 2022--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders today announced preliminary unaudited fourth quarter and full year 2021 net revenue results. |
Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceEXETER, N.H., November 22, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. |
Bullish insiders bet US$5.3m on Vapotherm, Inc. (NYSE:VAPO)Quite a few insiders have dramatically grown their holdings in Vapotherm, Inc. ( NYSE:VAPO ) over the past 12 months... |
Vapotherm (VAPO) Reports Q3 Loss, Tops Revenue EstimatesVapotherm (VAPO) delivered earnings and revenue surprises of -4.00% and 17.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
Vapotherm Reports Third Quarter 2021 Financial ResultsEXETER, N.H., November 03, 2021--Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company, today announced third quarter 2021 financial results. |